Dihydroergotamine Injection

Major

Dihydroergotamine Injection Diltiazem Cardizem Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Dronedarone Multaq Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Duvelisib Copiktra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Dihydroergotamine Injection Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Injection Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Dihydroergotamine Injection Fexinidazole An increased CYP3A4 substrate exposure Details Dihydroergotamine Injection Fluconazole Diflucan Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fluoxetine RECONCILE Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fluvoxamine Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fosnetupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Injection Imatinib Gleevec Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Dihydroergotamine Injection Isavuconazole Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Isavuconazonium Cresemba Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Ivacaftor Kalydeco Increased CYP3A substrate exposure Details Dihydroergotamine Injection Lanreotide Altered exposure to CYP3A4 substrate Details Dihydroergotamine Injection Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Injection Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Dihydroergotamine Injection Lenacapavir Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Injection Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Injection Lumacaftor Reduced exposure to CYP3A substrate Details Dihydroergotamine Injection Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Dihydroergotamine Injection Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dihydroergotamine Injection Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Dihydroergotamine Injection Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Dihydroergotamine Injection Netupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Nilotinib Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Dihydroergotamine Injection Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Dihydroergotamine Injection Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Injection Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Injection Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Dihydroergotamine Injection Pazopanib Votrient Increased dihydroergotamine concentrations and risk of ergot toxicity Details Dihydroergotamine Injection Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Dihydroergotamine Injection Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Propatyl Nitrate Increased risk of ergotism Details Dihydroergotamine Injection Propranolol Hemangeol Increased risk of coronary artery vasospasm Details